Results 211 to 220 of about 3,079 (276)

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

Hepatology Research, Volume 56, Issue 5, Page 861-866, May 2026.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C. Nelson Hayes, Masataka Tsuge, Shiro Oka   +21 more
wiley   +1 more source

The Expression of Alpha-Fetoprotein in Human Blastocoel Fluid-Conditioned Media In Vitro: A Proof of Concept Study. [PDF]

Int J Mol Sci
Kavoussi SK, Chen SH, Wininger JD, Lal A, Roudebush WE, Kavoussi PK, Esqueda AS, Chen J, Chosed RJ.   +8 more
europepmc   +1 more source

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

Hepatology Research, Volume 56, Issue 5, Page 830-839, May 2026.
ABSTRACT Background Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline
Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Hideki Onishi, Miwa Kawanaka, Akinobu Takaki, Kazuhiro Nouso, Kazuya Kariyama, Shinichiro Nakamura, Emi Tanaka, Toshifumi Tada, Tetsuya Yasunaka, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Masahiro Sakata, Motoyuki Otsuka   +20 more
wiley   +1 more source

Wertigkeit der regionalen Therapie des hepatozellulären Karzinoms [PDF]

, 2007
Dogan, Selin
core  

Construction of a nomogram for predicting the risk of primary liver cancer occurrence in patients with liver cysts using CT imaging features combined with alpha-fetoprotein. [PDF]

Medicine (Baltimore)
Jin ZL, Zhao LJ.
europepmc   +1 more source

Post‐to Pretreatment Ratio of Serum CXCL10 Level Predicts Short‐Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct‐Acting Antiviral Therapy

Hepatology Research, Volume 56, Issue 5, Page 840-852, May 2026.
The post‐to pretreatment serum CXCL10 ratio was independently associated with short‐term liver function outcome following HCV eradication in cirrhotic patients. ABSTRACT Aim The prognostic value of serum C‐X‐C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)–infected patients with compensated or ...
Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, Hayato Hikita, Masaru Enomoto, Atsunori Tsuchiya, Daiki Miki, Hiroshi Yatsuhashi, Hidekatsu Kuroda, Taro Yamashita, Hitoshi Yoshiji, Nobuharu Tamaki, Seiichi Mawatari, Hisamitsu Miyaaki, Yasuhiro Asahina, Yoichi Hiasa, Yoshihito Uchida, Yasunari Nakamoto, Taro Takami, Takahiro Kodama, Tetsuo Takehara   +20 more
wiley   +1 more source

Normalization of serum alpha fetoprotein after direct acting antivirals in hepatitis C patients lowers hepatocellular carcinoma risk. [PDF]

Sci Rep
Lin CK, Wang SH, Lee TH.
europepmc   +1 more source

National survey of real‐world treatment patterns for early‐ and intermediate‐stage hepatocellular carcinoma reveals wide variation across Australian states

Internal Medicine Journal, Volume 56, Issue 5, Page 858-867, May 2026.
Abstract Background Hepatocellular carcinoma (HCC) is a heterogeneous and multi‐disease state that is complex to manage and requires a multidisciplinary approach to optimise patient care. Best practice recommendations were proposed in the Australian HCC consensus statement published in 2020.
Stuart K. Roberts, Ammar Majeed, Kiran Rasaratnam, John K. Olynyk, Nicholas Shackel, Marnie Wood, Alan Wigg, Simone I. Strasser   +7 more
wiley   +1 more source

Alpha-Fetoprotein Stimulates Cleavage of Membranal MICA/B on Liver Cancer Cell Lead to Escape Immune Surveillance of Natural Killer Cells. [PDF]

J Cell Mol Med
Li X, Feng S, Wu X, Pan Y, Zhou Y, Liu K, Lin B, Li W, Li M, Zhu M.   +9 more
europepmc   +1 more source

Haemochromatosis – a modern clinician’s guide

Internal Medicine Journal, Volume 56, Issue 5, Page 777-783, May 2026.
Abstract Haemochromatosis is an inherited disorder of iron metabolism affecting approximately 100 000 Australians. Iron overload may result in end organ dysfunction, most commonly manifesting as chronic liver disease, arthropathy and endocrinopathies. End organ complications can be prevented, minimised or reversed, with early diagnosis and initiation ...
James G. Fiori, John K. Olynyk
wiley   +1 more source